Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood

Kitami Hayashi, Makiko Osawa, Masao Aihara, Tatsuro Izumi, Yoko Ohtsuka, Kazuhiro Haginoya, Ikuko Kato, Kenichiro Kaneko, Kenji Sugai, Takao Takahashi, Shin ichiro Hamano, Makoto Matsukura, Hisao Miura, Kimio Minagawa, Tsunekazu Yamano, Hitoshi Yamamoto, Hideo Yamanouchi, Hideto Yoshikawa

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

A retrospective multicenter study was conducted, designed to evaluate the efficacy and safety of midazolam for the treatment of status epilepticus. The subjects were 358 inpatients who received intravenous midazolam therapy for status epilepticus. The mean age was 48.6 ± 46.5 months. The underlying disorder was epilepsy in 195 cases, and acute symptomatic diseases in 163 (encephalitis or encephalopathy in 88 cases). Midazolam was administered as a bolus dose (0.25 ± 0.21 mg/kg), followed if necessary by continuous infusion (0.26 ± 0.25 mg/kg/hr). The bolus injection was effective in 162 (56.6%) of the 286 cases. In the end, seizure suppression was obtained in 231 cases (64.5% of the total). The effectiveness of midazolam was lower in patients in whom midazolam was initiated more than 3 hours after seizure onset, and this tendency was particularly marked in the epilepsy group. During the treatment period, 10 patients died, but none of these deaths were associated with midazolam therapy. The incidence and types of adverse events were consistent with previously reported data. The present results indicate that midazolam is highly effective for the management of status epilepticus, if used sufficiently early after seizure onset.

Original languageEnglish
Pages (from-to)366-372
Number of pages7
JournalPediatric Neurology
Volume36
Issue number6
DOIs
Publication statusPublished - 2007 Jun

Fingerprint

Status Epilepticus
Midazolam
Seizures
Epilepsy
Brain Diseases
Acute Disease
Encephalitis
Therapeutics
Multicenter Studies
Inpatients
Retrospective Studies
Safety
Injections
Incidence

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Hayashi, K., Osawa, M., Aihara, M., Izumi, T., Ohtsuka, Y., Haginoya, K., ... Yoshikawa, H. (2007). Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood. Pediatric Neurology, 36(6), 366-372. https://doi.org/10.1016/j.pediatrneurol.2007.02.012

Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood. / Hayashi, Kitami; Osawa, Makiko; Aihara, Masao; Izumi, Tatsuro; Ohtsuka, Yoko; Haginoya, Kazuhiro; Kato, Ikuko; Kaneko, Kenichiro; Sugai, Kenji; Takahashi, Takao; Hamano, Shin ichiro; Matsukura, Makoto; Miura, Hisao; Minagawa, Kimio; Yamano, Tsunekazu; Yamamoto, Hitoshi; Yamanouchi, Hideo; Yoshikawa, Hideto.

In: Pediatric Neurology, Vol. 36, No. 6, 06.2007, p. 366-372.

Research output: Contribution to journalArticle

Hayashi, K, Osawa, M, Aihara, M, Izumi, T, Ohtsuka, Y, Haginoya, K, Kato, I, Kaneko, K, Sugai, K, Takahashi, T, Hamano, SI, Matsukura, M, Miura, H, Minagawa, K, Yamano, T, Yamamoto, H, Yamanouchi, H & Yoshikawa, H 2007, 'Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood', Pediatric Neurology, vol. 36, no. 6, pp. 366-372. https://doi.org/10.1016/j.pediatrneurol.2007.02.012
Hayashi K, Osawa M, Aihara M, Izumi T, Ohtsuka Y, Haginoya K et al. Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood. Pediatric Neurology. 2007 Jun;36(6):366-372. https://doi.org/10.1016/j.pediatrneurol.2007.02.012
Hayashi, Kitami ; Osawa, Makiko ; Aihara, Masao ; Izumi, Tatsuro ; Ohtsuka, Yoko ; Haginoya, Kazuhiro ; Kato, Ikuko ; Kaneko, Kenichiro ; Sugai, Kenji ; Takahashi, Takao ; Hamano, Shin ichiro ; Matsukura, Makoto ; Miura, Hisao ; Minagawa, Kimio ; Yamano, Tsunekazu ; Yamamoto, Hitoshi ; Yamanouchi, Hideo ; Yoshikawa, Hideto. / Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood. In: Pediatric Neurology. 2007 ; Vol. 36, No. 6. pp. 366-372.
@article{ebfc594c70b747a79d58491abaf503e6,
title = "Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood",
abstract = "A retrospective multicenter study was conducted, designed to evaluate the efficacy and safety of midazolam for the treatment of status epilepticus. The subjects were 358 inpatients who received intravenous midazolam therapy for status epilepticus. The mean age was 48.6 ± 46.5 months. The underlying disorder was epilepsy in 195 cases, and acute symptomatic diseases in 163 (encephalitis or encephalopathy in 88 cases). Midazolam was administered as a bolus dose (0.25 ± 0.21 mg/kg), followed if necessary by continuous infusion (0.26 ± 0.25 mg/kg/hr). The bolus injection was effective in 162 (56.6{\%}) of the 286 cases. In the end, seizure suppression was obtained in 231 cases (64.5{\%} of the total). The effectiveness of midazolam was lower in patients in whom midazolam was initiated more than 3 hours after seizure onset, and this tendency was particularly marked in the epilepsy group. During the treatment period, 10 patients died, but none of these deaths were associated with midazolam therapy. The incidence and types of adverse events were consistent with previously reported data. The present results indicate that midazolam is highly effective for the management of status epilepticus, if used sufficiently early after seizure onset.",
author = "Kitami Hayashi and Makiko Osawa and Masao Aihara and Tatsuro Izumi and Yoko Ohtsuka and Kazuhiro Haginoya and Ikuko Kato and Kenichiro Kaneko and Kenji Sugai and Takao Takahashi and Hamano, {Shin ichiro} and Makoto Matsukura and Hisao Miura and Kimio Minagawa and Tsunekazu Yamano and Hitoshi Yamamoto and Hideo Yamanouchi and Hideto Yoshikawa",
year = "2007",
month = "6",
doi = "10.1016/j.pediatrneurol.2007.02.012",
language = "English",
volume = "36",
pages = "366--372",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood

AU - Hayashi, Kitami

AU - Osawa, Makiko

AU - Aihara, Masao

AU - Izumi, Tatsuro

AU - Ohtsuka, Yoko

AU - Haginoya, Kazuhiro

AU - Kato, Ikuko

AU - Kaneko, Kenichiro

AU - Sugai, Kenji

AU - Takahashi, Takao

AU - Hamano, Shin ichiro

AU - Matsukura, Makoto

AU - Miura, Hisao

AU - Minagawa, Kimio

AU - Yamano, Tsunekazu

AU - Yamamoto, Hitoshi

AU - Yamanouchi, Hideo

AU - Yoshikawa, Hideto

PY - 2007/6

Y1 - 2007/6

N2 - A retrospective multicenter study was conducted, designed to evaluate the efficacy and safety of midazolam for the treatment of status epilepticus. The subjects were 358 inpatients who received intravenous midazolam therapy for status epilepticus. The mean age was 48.6 ± 46.5 months. The underlying disorder was epilepsy in 195 cases, and acute symptomatic diseases in 163 (encephalitis or encephalopathy in 88 cases). Midazolam was administered as a bolus dose (0.25 ± 0.21 mg/kg), followed if necessary by continuous infusion (0.26 ± 0.25 mg/kg/hr). The bolus injection was effective in 162 (56.6%) of the 286 cases. In the end, seizure suppression was obtained in 231 cases (64.5% of the total). The effectiveness of midazolam was lower in patients in whom midazolam was initiated more than 3 hours after seizure onset, and this tendency was particularly marked in the epilepsy group. During the treatment period, 10 patients died, but none of these deaths were associated with midazolam therapy. The incidence and types of adverse events were consistent with previously reported data. The present results indicate that midazolam is highly effective for the management of status epilepticus, if used sufficiently early after seizure onset.

AB - A retrospective multicenter study was conducted, designed to evaluate the efficacy and safety of midazolam for the treatment of status epilepticus. The subjects were 358 inpatients who received intravenous midazolam therapy for status epilepticus. The mean age was 48.6 ± 46.5 months. The underlying disorder was epilepsy in 195 cases, and acute symptomatic diseases in 163 (encephalitis or encephalopathy in 88 cases). Midazolam was administered as a bolus dose (0.25 ± 0.21 mg/kg), followed if necessary by continuous infusion (0.26 ± 0.25 mg/kg/hr). The bolus injection was effective in 162 (56.6%) of the 286 cases. In the end, seizure suppression was obtained in 231 cases (64.5% of the total). The effectiveness of midazolam was lower in patients in whom midazolam was initiated more than 3 hours after seizure onset, and this tendency was particularly marked in the epilepsy group. During the treatment period, 10 patients died, but none of these deaths were associated with midazolam therapy. The incidence and types of adverse events were consistent with previously reported data. The present results indicate that midazolam is highly effective for the management of status epilepticus, if used sufficiently early after seizure onset.

UR - http://www.scopus.com/inward/record.url?scp=34249872188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249872188&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2007.02.012

DO - 10.1016/j.pediatrneurol.2007.02.012

M3 - Article

VL - 36

SP - 366

EP - 372

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 6

ER -